Harnessing CD8<sup>+</sup>CD28<sup>−</sup> Regulatory T Cells as a Tool to Treat Autoimmune Disease
T regulatory cell therapy presents a novel therapeutic strategy for patients with autoimmune diseases or who are undergoing transplantation. At present, the CD4<sup>+</sup> Treg population has been extensively characterized, as a result of defined phenotypic and functional readouts. In t...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-11-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/10/11/2973 |
| Summary: | T regulatory cell therapy presents a novel therapeutic strategy for patients with autoimmune diseases or who are undergoing transplantation. At present, the CD4<sup>+</sup> Treg population has been extensively characterized, as a result of defined phenotypic and functional readouts. In this review article, we discuss the development and biology of CD8<sup>+</sup> Tregs and their role in murine and human disease indications. A subset of CD8<sup>+</sup> Tregs that lack the surface expression of CD28 (CD8<sup>+</sup>CD28<sup>−</sup> Treg) has proved efficacious in preclinical models. CD8<sup>+</sup>CD28<sup>−</sup> Tregs are present in healthy individuals, but their impaired functionality in disease renders them less effective in mediating immunosuppression. We primarily focus on harnessing CD8<sup>+</sup> Treg cell therapy in the clinic to support current treatment for patients with autoimmune or inflammatory conditions. |
|---|---|
| ISSN: | 2073-4409 |